Physician profile
James Kerner
NPI 1962429563
$4,234.04
in general payments reported to CMS, 2019-2025
27 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $602 · 2021: $435 · 2022: $541 · 2023: $789 · 2024: $1,036 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,158.57 |
| Education | $238.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.39 | 2019-2025 | |
| Genzyme Corporation | $502.62 | 2019-2025 | |
| Janssen Biotech, INC. | $429.07 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $371.14 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $278.37 | 2020-2024 | Dupixent, Libtayo |
| Incyte Corporation | $236.42 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $205.76 | 2022-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $154.17 | 2023-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $144.00 | 2019-2020 | |
| Allergan, INC. | $129.25 | 2020-2021 | |
| Ucb, INC. | $126.26 | 2019-2025 | Bimzelx |
| Lilly USA, LLC | $124.94 | 2021-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $113.71 | 2021-2024 | Ilumya |
| Novartis Pharmaceuticals Corporation | $90.03 | 2023-2025 | |
| Arcutis Biotherapeutics, INC. | $74.83 | 2023-2024 | Zoryve |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $74.43 | 2024 | Vyjuvek |
| Galderma Laboratories, L.P. | $62.32 | 2020-2025 | Nemluvio |
| Organon LLC | $35.14 | 2025 | Vtama |
| Pfizer INC. | $26.10 | 2019-2023 | |
| Sandoz INC. | $23.87 | 2024 | Hyrimoz |
| Blueprint Medicines Corporation | $22.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.24 | 2024 | Spevigo |
| Celgene Corporation | $16.78 | 2019 | |
| Smith+Nephew, INC. | $15.89 | 2025 | Collagenase Santyl |
| Kyowa Kirin, INC. | $15.50 | 2022 | |
| Merck Sharp & Dohme LLC | $15.02 | 2023 | Keytruda |
| Prugen, INC. Pharmaceuticals | $8.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.